RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:The other two clinics Depends on what you mean as dangerous since they are already using docetaxal as a chemo agent. If you see no response or limited response, it's not a suitable treatment for the patient. It won't be 100% repsonse, so this will happen a lot, and does already with chemo.
This is the scenario JFM has highlighted as to why it would be highly useful in the future to attach some kind of relatively harmless radionuclear marker to the PDC instead of the chemo and then image it so you can see if the tumor has massive overexpression and sortilin and where else the sortilin may be overexpressed in the body. Then you know the patient should response or not since it all depends on the overexpression of sortilin in the tumor cells. It's a great idea and I'm sure Marsolais is aware of it at this point and after they find out if there is actual efficacy, it would be interesting to see if they want to develop this kind of response test.
realitycheck4u wrote: Isn't this rather dangerous to do a trial where the patient has not been pre-screened for Sortilin then?? And if there is not sortilin to attract the PDC then what happens to the payload. Does it release anyhow